Drugs / PF-5212372
PF-5212372
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01415102 | Sep → Dec 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02795832 | Jun 2016 → Mar 2017 | atopic eczema | Ziarco Pharma Ltd | Completed | Mixed |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-5212372 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650312 ↗ |
| Known as | PF-05212372 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01415102 ↗ |
| Known as | PLA-950 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650312 ↗ |
| Known as | ZPL-521 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650312 ↗ |
| Known as | ZPL-5212372 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02795832 ↗ |
| Modality | Small molecule | — CHEMBL4650312 ↗ |
| Route | Inhaled | “Inhaled. Dose Level 1: 50 ug” NCT01415102 ↗ |